louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01622595: UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
Official title: A Non-interventional Observational Study of Infectious Complications in Cancer Patients
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Aspergillosis
Candidemia
C. Difficile
Keywords: Aspergillosis
Candidemia
Candidiasis
C. Difficile
cytomegalovirus
respiratory syncytial virus (RSV)
Influenza
CONS
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2012-06-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer patients with Infections

Brief summary: OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS

Detailed description: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS

Eligibility criteria: Inclusion Criteria:

* cancer patients with Infections

Exclusion Criteria:

* No Infections

Primary outcomes:
measure: To study the incidence, risk factors, clinical presentation, diagnosis and prognostic factors of infectious complications in cancer patients
timeFrame: 3 years
Secondary outcomes:
measure: incidence
timeFrame: 3 years
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
Study officials:
affiliation: UAMS
name: Senu Apewokin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05720195: ALBI and PALBI Scores and HCC Prognosis
Official title: Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma (HCC) Prognosis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-02-09
Enrollment: 645
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will include all patients diagnosed with HCC both males and females equal to or above 18 years old, attending the outpatient clinic or admitted at the inpatient section of Tropical Medicine and Gastroenterology Department, Sohag University Hospital

Brief summary: To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.

To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.


Eligibility criteria: Inclusion Criteria:

• The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.

Exclusion Criteria:

* Patients below 18 years old.
* Patients with pre-existing other malignancies.
* Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases.
* Patients with pre-existing haematologic disorders.
* Patients with proteinuria.
* Missed follow-up.

Primary outcomes:
measure: Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score
timeFrame: 2 years
measure: Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score
timeFrame: 2 years
Secondary outcomes:
measure: Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score
timeFrame: 2 years
measure: Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)
timeFrame: 2 years
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
References:
Clinical trial NCT03226795: Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals
Official title: Improving Therapeutic Adherence of Adult Patients With Cystic Fibrosis: Impact of a Co-constructed Program by Patients and Health Caregivers.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cystic Fibrosis
Keywords: Cystic fibrosis
Therapeutic adherence
Co-constructed intervention
Patient involvement
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Background Cystic fibrosis is a life-threatening genetic disorder responsible for pulmonary failure and multi-systemic complications involving specific and large medical care burden. To date, no program has shown its effectiveness in improving therapeutic adherence. A new approach to develop a co-constructed program involving patients and professionals may contribute to improve therapeutic adherence.

Objectives The aim of the MUCOBS-Trial project is to create a program to increase therapeutic adherence and to evaluate its efficacy in adult patients with cystic fibrosis in 3 CF centers in France.


Eligibility criteria: Inclusion Criteria:

* Patients with Cystic Fibrosis
* Aged 18 or more
* Speaking / understanding French
* Followed in one of the participating centers (CRCM of the Auvergne-Rhône-Alpes region)
* Resident in Auvergne-Rhône-Alpes
* Affiliated to the general health insurance scheme

Exclusion Criteria:

* Transplanted Patients
* Patients who participated in the working group for the co-construction of the intervention

Primary outcomes:
measure: Medication Adherence (coverage rate)
timeFrame: 18 months.
Secondary outcomes:
measure: Adherence to medications for obstructive airway syndromes
timeFrame: 18 months.
measure: Adherence to physiotherapy
timeFrame: 18 months
measure: Adherence score evaluated by self-administered questionnaire
timeFrame: 6 and 18 months
measure: Cystic Fibrosis Knowledge Scale
timeFrame: 6 and 18 months
measure: Quality of life measured by Cystic fibrosis Questionnaire (CFQ-R)
timeFrame: 6 and 18 months
measure: Clinical evolution : Forced expiratory volume in 1 s as a percentage of predicted (%FEV1)
timeFrame: 18 months
measure: Clinical evolution : body mass index (BMI)
timeFrame: 18 months
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CRCM mixte, Hôpital Estaing
city: La Tronche
country: France
facility: CRCM Adulte CHU Grenoble Alpes
city: Pierre-Bénite
country: France
facility: Centre de Ressources et de Compétences de la Mucoviscidose adulte de Lyon - Centre Hospitalier Lyon Sud
Study officials:
References:
Clinical trial NCT04134195: The Effect of Transcranial Direct Current Stimulation on Visual Attention - Single Sessions
Official title: The Effect of Transcranial Direct Current Stimulation on Visual Attention - a Combined MRI and Non-invasive Brain Stimulation Single Session Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Aging
Cognitive Change
Cognitive Decline
Keywords: Transcranial direct current stimulation
Healthy seniors
Healthy adults
Lead sponsor: Masaryk University
Sponsor class: OTHER
Collaborators: name: St. Anne's University Hospital Brno, Czech Republic
First posted: 2019-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Recently, attention has been drawn to non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), in order to enhance cognitive functions by modifying brain plasticity and use it in different healthy and diseased populations. In the current research, investigator aim to examine the short-term effects of multiple tDCS protocols in healthy adults population on visual attention and identify the neural underpinnings of tDCS-induced behavioral aftereffects using a combined tDCS/ MRI network-based approach.

Detailed description: Investigator will investigate the shor-term effects of active tDCS as compared to a placebo stimulation on visual attention in the healthy seniors. A cross-over, randomized, placebo-controlled design will be used. Single tDCS sessions will be performed in 4 sessions over distinct brain areas with ongoing visual attention training. During the stimulation, investigator will use the visual matching task. MRI protocol consisting of T1 and resting state fMRI sequences will be acquired before and after every stimulation session in order to search for active vs. placebo tDCS-induced changes in brain activation and resting state functional connectivity and to identify neural correlates of behavioral changes.

Eligibility criteria: Inclusion Criteria:

* right handed, healthy volunteers in two groups - healthy adults under 40 years, healthy seniors over 50 years

Exclusion Criteria:

* psychiatric disorders, including major depression, major vascular lesions, and other brain pathologies detected by MRI that might present with cognitive decline

  * a cardio pacemaker or any MRI-incompatible metal in the body
  * epilepsy
  * any diagnosed psychiatric disorder
  * alcohol/drug abuse
  * lack of cooperation
  * presence of cognitive impairment

Primary outcomes:
measure: Visual-attention task accuracy
timeFrame: Change from baseline immediately after completion of stimulation protocol
measure: Magnetic resonance imaging
timeFrame: Change from baseline immediately after completion of stimulation protocol
Secondary outcomes:
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: Ceitec, Masaryk University
Study officials:
affiliation: Ceitec, Masaryk University
name: Ľubomira Nováková
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00577395: Bone Microarchitecture in Osteopenic Postmenopausal Women
Official title: A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging).
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Osteoporosis
Lead sponsor: Warner Chilcott
Sponsor class: INDUSTRY
Collaborators: name: Sanofi
First posted: 2007-12-20
Enrollment: 13
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 57
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to compare the difference in bone microarchitecture of the distal radius at month 12 in postmenopausal osteopenic women treated with risedronate 150mg taken once a month compared to placebo.


Eligibility criteria: Inclusion Criteria:

* Female: 40 and 57 years of age inclusive
* cessation of menstruation (surgical or natural) between 12 and 36 months prior to study enrollment
* have osteopenia defines as having the following: have osteopenia defined as having the following:
* Lumbar spine (L1-L4) Bone Mineral Density (BMD) T score -1 and less than -2.5 AND a total hip T score of greater than -2.5 OR
* Lumbar spine (L1-L4) BMD T score greater than -2.5 AND a total hip T score -1 and less than -2.5;
* have a body mass index (BMI) between 18 and 30 kg/m2.

Exclusion Criteria:

* history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia
* use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone
* hypocalcemia or hypercalcemia of any cause

Primary outcomes:
measure: Percent Change From Baseline in Erosion Index (A Ratio of Curve-like Structures to Plate-like Structures and is a Measure of the Degree of Structural Degradation) of the Distal Radius
timeFrame: 12 months
Secondary outcomes:
measure: Erosion Index of the Distal Radius
timeFrame: 6 months
Other outcomes:
Locations:
city: Tuscon
country: United States
facility: Research Facility
state: Arizona
city: Omaha
country: United States
facility: Research Facility
state: Nebraska
city: Cincinnati
country: United States
facility: Research Site
state: Ohio
city: Buenos Aires
country: Argentina
facility: Research Facility
Study officials:
affiliation: Procter and Gamble
name: Ana M Balske, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Official title: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Atopic Dermatitis
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2024-05-03
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.

Detailed description: Patients will sign an informed consent and assent to participate. Skin and both nares will be cultured for S aureus. A blood sample and two 2 mm skin biopsies will be obtained one from non-lesional skin and another one from lesional skin). The patients will be instructed in the use of the three-week S. aureus decolonization regimen and provided with the medications (sulfamethoxazole/trimethoprim and Mupirocin ointment) and Chlorhexidine. The second visit will take place immediately at the end of the three-week S. aureus skin decolonization regimen. Disease severity will be assessed, the skin and nares will be re-cultured, and skin biopsies and blood will be obtained.

Eligibility criteria: Inclusion Criteria:

1. Male or female participants ≥6 yrs of age
2. Meet atopic dermatitis Standard Diagnostic Criteria
3. SCORAD \> 40.

Exclusion Criteria:

1. . Enrollment in another clinical trial
2. Hypersensitivity to an agent used for the skin decolonization protocol
3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, azathioprine, methotrexate)
4. Phototherapy for AD within 4 weeks
5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
6. Use of topical steroids, topical calcineurin inhibitors within 7 days
7. Bleach baths within 7 days of the first Visit
8. Use of oral or topical antibiotics within 21 days of the beginning of the study
9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
13. Febrile illness at time of visits
14. Suspected immune deficiency or family history of primary immunodeficiency
15. Pregnancy

Primary outcomes:
measure: Severity Scoring of Atopic Dermatitis Index
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT06863181: Comparison of Conventional and Cooled Radiofrequency Ablation in Knee Osteoarthritis
Official title: Comparison of the Effectiveness of Conventional and Cooled Radiofrequency Ablation in Advanced Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Sponsor class: OTHER
First posted: 2025-03-07
Enrollment: 26
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to examine and compare the effects of conventional and cooled radiofrequency ablation on pain and disability levels in patients with knee pain resistant to other treatments due to knee osteoarthritis.


Eligibility criteria: Inclusion Criteria:

* Knee pain lasting more than 6 months
* Age between 50 and 80
* Diagnosis of radiographically proven grade III or IV knee osteoarthritis according to the Kellgren-Lawrence Grading Scale, marked narrowing of the medial compartment of the tibiofemoral joint space
* Presence of pain resistant to conservative treatment

  * Exercise
  * Physical therapy agents
  * Use of oral anti-inflammatory agents

Exclusion Criteria:

* History of trauma to the knee area
* History of knee surgery
* Presence of systemic inflammatory disease affecting the knee joint
* Presence of peripheral neuropathy or radiculopathy
* Pregnancy
* Hemodynamic instability
* Presence of skin or soft tissue infection at the injection site
* Refusal to participate in the study
* Presence of acute knee pain with accompanying inflammatory findings
* Presence of a serious psychiatric disorder or neurological disease Having received an intra-articular injection within the last 3 months

Primary outcomes:
measure: Visual Analog Scale (VAS)
timeFrame: Before treatment (0. week), 4 weeks after treatment (4.week), 12 weeks after treatment (12.week)
Secondary outcomes:
measure: Western Ontario and McMaster Universities Arthritis Index (WOMAC)
timeFrame: Before treatment (0. week), 4 weeks after treatment (4.week), 12 weeks after treatment (12.week)
measure: 5-Point Likert Patient Satisfaction Scale
timeFrame: Before treatment (0. week), 4 weeks after treatment (4.week), 12 weeks after treatment (12.week)
measure: Change in frequency of analgesic use
timeFrame: Before treatment (0. week), 4 weeks after treatment (4.week), 12 weeks after treatment (12.week)
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gaziler Physical Medicine and Rehabilitation Training and Research Hospital
state: Çankaya
Study officials:
References:
Clinical trial NCT01104181: Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test
Official title: Collection of Anal Specimens for Assessment of Anal Cancer Using the HC2 High-Risk DNA Test (QIAGEN)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anal Canal HPV Infection Diagnosis
Anal Dysplasia Diagnosis
Anal Cancer
Keywords: Anal HPV
Anal Dysplasia
Ana Cancer
Lead sponsor: Laser Surgery Care
Sponsor class: OTHER
Collaborators: name: QIAGEN Gaithersburg, Inc
First posted: 2010-04-15
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is a study to determine if HC2 HPV testing in the anal canal can detect high-risk HPV and whether this aids in identifying individuals are risk for anal cancer or precancerous lesions.


Eligibility criteria: Inclusion Criteria:

1. male or female 18 years of age or older
2. screened for anal dysplasia, including MSM and women -

Exclusion Criteria:

1. subject has had a previous treatment for anal cancer.
2. subjects that have used enemas or other foreign substances, in the anal canal or anal sex within 24 hours of collection.
3. subjects that have bleeding disorders or use anticoagulation treatments. -

Primary outcomes:
measure: HC2 can accurately test for oncogenic HPV in anal specimens
timeFrame: in approximately 12 months
Secondary outcomes:
measure: Sensitivity and specificity of cytology with HC2
timeFrame: in approximately 12 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Laser Surgery Care, Inc.
state: New York
Study officials:
affiliation: Mount Sinai Medical School
name: Stephen E Goldstone, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00305981: The ICU Care Knowledge Study
Official title: The ICU Care Knowledge Study: A Prospective Study of Family Members' Knowledge of ICU Care and Prognosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ICU Patient
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2006-03-22
Enrollment: 154
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Family members have poor overall understanding of ICU patients' prognosis, resuscitation status and care, defined a priori as less than 75% correct responses to the yes/no ICU care questions.

Family members of all adult patients admitted to an intensive care of San Francisco General Hospital will be screened for enrollment and recruited sequentially over a period of nine months (August 1, 2005-March 31, 2006). We will determine the frequency of family members' correct responses to the survey questions about ICU care. Family member responses will be compared to the chart and real-time patient observation reality (gold standard).

Hypothesis # 2 Poor English language comprehension and low education level (defined as not having completed high school) are risk factors for poor ICU care understanding and knowledge.

During their surveys family members will be asked questions regarding their English language comprehension and education level. Association of these possible risk factors with low level of ICU care knowledge will be tested primarily using analysis of variance. Should our hypothesis #2 prove to be correct, our future goal will be to develop recommendations for interventions to increase understanding specific for these high risk groups. One of these interventions is described in Hypothesis #3 below.

Hypothesis # 3 Provision of the results of family members' knowledge assessment to health care providers will result in improved ICU care knowledge on subsequent testing.

Subjects will be randomized to two groups-one group's health care providers will be shown the results of family members' initial ICU knowledge assessment; the other group's providers will not be given these results. One to two days after providing this summary to providers, all randomized subjects will undergo a second interview assessing their ICU care knowledge. Changes in the frequency of correct responses between the two groups will be compared using mean differences in proportions with 95% confidence intervals.


Eligibility criteria: Inclusion Criteria:

* family member of ICU patient

Exclusion Criteria:

* incarceration, unable to participate in interview

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: San Francisco General Hospital ICU
state: California
Study officials:
affiliation: San Francisco General Hospital
name: Robert M Rodriguez, MD
role: PRINCIPAL_INVESTIGATOR
References: